{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:52:40Z","timestamp":1781628760603,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The Beyond Batten Disease Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Institutional support from the Department of Pediatrics, Washington University in St. Louis","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NINDS R01 NS124655"],"award-info":[{"award-number":["NINDS R01 NS124655"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    CLN1 disease, one of the most severe forms of neuronal ceroid lipofuscinosis (NCLs or Batten disease), is a rapidly progressing pediatric neurodegenerative disorder caused by mutations in the\n                    <jats:italic>PPT1<\/jats:italic>\n                    gene. The disease is characterized by lysosomal storage accumulation, an early onset neuroimmune response, motor impairment, and premature death. N-acetyl-L-leucine (NALL), an orally bioavailable modified amino acid, has demonstrated clinical efficacy in Niemann\u2013Pick type C and other lysosomal storage disorders. Here, we assessed the efficacy of chronic NALL treatment in the\n                    <jats:italic>Ppt1<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>\u2212\/\u2212<\/jats:italic>\n                    <\/jats:sup>\n                    mouse model of CLN1 disease. Mice received NALL (0.1\u00a0g\/kg\/day) in chow either from weaning (1 month, presymptomatic) or from 4 months (symptomatic) until 7 months (normal disease endstage), with additional survival cohorts. NALL treatment did not extend survival in\n                    <jats:italic>Ppt1<\/jats:italic>\n                    <jats:sup>\n                      <jats:italic>\u2212\/\u2212<\/jats:italic>\n                    <\/jats:sup>\n                    mice and produced no significant improvement in gait coordination or rotarod performance, with only minimal improvements in select gait variability parameters in presymptomatically treated mice. Histological analyses revealed no reduction in microglial or astrocyte activation, nor in storage material accumulation, key CLN1 disease-associated phenotypes. These findings indicate that NALL monotherapy has limited therapeutic efficacy in CLN1 disease mice and suggest that its mechanisms of action may not address the underlying pathophysiology of this disorder.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-32984-x","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T09:46:34Z","timestamp":1767001594000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Limited therapeutic efficacy of N-acetyl-L-leucine in a mouse model of CLN1 disease"],"prefix":"10.1038","volume":"16","author":[{"given":"Ewa A.","family":"Zi\u00f3\u0142kowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole A.","family":"Pag\u00e1n Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsintsung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letitia L.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Eultgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Nowacka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua T.","family":"Dearborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemanth R.","family":"Nelvagal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ineka T.","family":"Whiteman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances M.","family":"Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"32984_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1474-4422(18)30368-5","volume":"18","author":"SE Mole","year":"2019","unstructured":"Mole, S. E. et al. Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis. Lancet Neurol. 18, 107\u2013116 (2019).","journal-title":"Lancet Neurol."},{"key":"32984_CR2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41582-019-0138-8","volume":"15","author":"TB Johnson","year":"2019","unstructured":"Johnson, T. B. et al. Therapeutic landscape for Batten disease: current treatments and future prospects. Nat. Reviews Neurol. 15, 161\u2013178 (2019).","journal-title":"Nat. Reviews Neurol."},{"key":"32984_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-025-01132-4","author":"EA Zi\u00f3\u0142kowska","year":"2025","unstructured":"Zi\u00f3\u0142kowska, E. A. et al. Neuronal ceroid lipofuscinosis: underlying mechanisms and emerging therapeutic targets. Nat. Rev. Neurol. https:\/\/doi.org\/10.1038\/s41582-025-01132-4 (2025). Online ahead of print.","journal-title":"Nat. Rev. Neurol."},{"key":"32984_CR4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/0022-510X(73)90075-0","volume":"18","author":"P Santavuori","year":"1973","unstructured":"Santavuori, P., Haltia, M., Rapola, J. & Raitta, C. Infantile type of so-called neuronal ceroid-lipofuscinosis. J. Neurol. Sci. 18, 257\u2013267 (1973).","journal-title":"J. Neurol. Sci."},{"key":"32984_CR5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.pediatrneurol.2021.04.002","volume":"120","author":"EF Augustine","year":"2021","unstructured":"Augustine, E. F. et al. Management of CLN1 disease: international clinical consensus. Pediatr. Neurol. 120, 38\u201351 (2021).","journal-title":"Pediatr. Neurol."},{"key":"32984_CR6","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/j.bbadis.2012.11.014","volume":"1832","author":"G Anderson","year":"2013","unstructured":"Anderson, G., Goebel, H. H. & Simonati, A. Human pathology in NCL. Biochim. Biophys. Acta. 1832, 1807\u20131826 (2013).","journal-title":"Biochim. Biophys. Acta"},{"key":"32984_CR7","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/376584a0","volume":"376","author":"J Vesa","year":"1995","unstructured":"Vesa, J. et al. Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis. Nature 376, 584\u2013587 (1995).","journal-title":"Nature"},{"key":"32984_CR8","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1750-3639.2004.tb00077.x","volume":"14","author":"J Tyynel\u00e4","year":"2006","unstructured":"Tyynel\u00e4, J., Cooper, J. D., Khan, M. N., Shemilt, S. J. A. & Haltia, M. Hippocampal pathology in the human neuronal ceroid-lipofuscinoses: distinct patterns of storage deposition, neurodegeneration and glial activation. Brain Pathol. 14, 349\u2013357 (2006).","journal-title":"Brain Pathol."},{"key":"32984_CR9","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1007\/s00401-005-0024-x","volume":"111","author":"Y Hachiya","year":"2006","unstructured":"Hachiya, Y. et al. Mechanisms of neurodegeneration in neuronal ceroid-lipofuscinoses. Acta Neuropathol. 111, 168\u2013177 (2006).","journal-title":"Acta Neuropathol."},{"key":"32984_CR10","doi-asserted-by":"crossref","unstructured":"Nelvagal, H. R. et al. Cross-species efficacy of enzyme replacement therapy for CLN1 disease in mice and sheep. J. Clin. Invest. 132 (2022).","DOI":"10.1172\/JCI163107"},{"key":"32984_CR11","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.nbd.2004.03.005","volume":"16","author":"MA Griffey","year":"2004","unstructured":"Griffey, M. A. et al. Adeno-associated virus 2-mediated gene therapy decreases autofluorescent storage material and increases brain mass in a murine model of infantile neuronal ceroid lipofuscinosis. Neurobiol. Dis. 16, 360\u2013369 (2004).","journal-title":"Neurobiol. Dis."},{"key":"32984_CR12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ymthe.2005.04.018","volume":"12","author":"MA Griffey","year":"2005","unstructured":"Griffey, M. A., Macauley, S. L., Ogilvie, J. M. & Sands, M. S. AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis. Mol. Ther. 12, 413\u2013421 (2005).","journal-title":"Mol. Ther."},{"key":"32984_CR13","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.ymthe.2005.11.008","volume":"13","author":"MA Griffey","year":"2006","unstructured":"Griffey, M. A. et al. CNS-directed AAV2-mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis. Mol. Ther. 13, 538\u2013547 (2006).","journal-title":"Mol. Ther."},{"key":"32984_CR14","doi-asserted-by":"publisher","first-page":"201701832","DOI":"10.1073\/pnas.1701832114","volume":"114","author":"C Shyng","year":"2017","unstructured":"Shyng, C. et al. Synergistic effects of treating the spinal cord and brain in CLN1 disease. Proc. Natl. Acad. Sci. U.S.A. 114, 201701832 (2017).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"32984_CR15","doi-asserted-by":"crossref","unstructured":"Davis, L. et al. Stereospecific rapid activation of Transcription Factor EB (TFEB) by Levacetylleucine (NALL). Biorxiv Preprint (2025).","DOI":"10.1101\/2025.06.06.657607"},{"key":"32984_CR16","doi-asserted-by":"publisher","first-page":"15812","DOI":"10.1038\/s41598-021-95255-5","volume":"11","author":"GC Churchill","year":"2021","unstructured":"Churchill, G. C. et al. Acetylation turns leucine into a drug by membrane transporter switching. Sci. Rep. 11, 15812 (2021).","journal-title":"Sci. Rep."},{"issue":"12","key":"32984_CR17","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.clinthera.2024.10.011","volume":"46","author":"P. Beninger","year":"2024","unstructured":"Beninger, P. Aqneursa (levacetylleucine). Clin. Ther. 46 (12), 1091\u20131092 (2024).","journal-title":"Clin. Ther."},{"key":"32984_CR18","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/d41573-024-00162-9","volume":"23","author":"A. Mullard","year":"2024","unstructured":"Mullard, A. FDA approves first two drugs for rare Niemann\u2013Pick disease. Nat. Rev. Drug Discovery. 23, 804 (2024).","journal-title":"Nat. Rev. Drug Discovery"},{"key":"32984_CR19","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.tips.2025.02.003","volume":"46","author":"R van Gool","year":"2025","unstructured":"van Gool, R., Al-Hertani, W., Bodamer, O. & Upadhyay, J. Levacetylleucine (N-acetyl-l-leucine) for Niemann-Pick disease type C. Trends Pharmacol. Sci. 46, 386\u2013387 (2025).","journal-title":"Trends Pharmacol. Sci."},{"key":"32984_CR20","doi-asserted-by":"publisher","first-page":"fcaa148","DOI":"10.1093\/braincomms\/fcaa148","volume":"3","author":"E. Kaya","year":"2021","unstructured":"Kaya, E. et al. Acetyl-leucine slows disease progression in lysosomal storage disorders. Brain Commun. 3, fcaa148 (2021).","journal-title":"Brain Commun."},{"key":"32984_CR21","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.3390\/jcm9041050","volume":"9","author":"E Kaya","year":"2020","unstructured":"Kaya, E. et al. Beneficial effects of Acetyl-DL-Leucine (ADLL) in a mouse model of Sandhoff disease. J. Clin. Med. 9, 1050 (2020).","journal-title":"J. Clin. Med."},{"key":"32984_CR22","doi-asserted-by":"publisher","first-page":"9249","DOI":"10.1038\/s41598-021-88693-8","volume":"11","author":"N Hegdekar","year":"2021","unstructured":"Hegdekar, N., Lipinski, M. M. & Sarkar, C. N-Acetyl-l-leucine improves functional recovery and attenuates cortical cell death and neuroinflammation after traumatic brain injury in mice. Sci. Rep. 11, 9249 (2021).","journal-title":"Sci. Rep."},{"key":"32984_CR23","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1056\/NEJMoa2310151","volume":"390","author":"T Bremova-Ertl","year":"2024","unstructured":"Bremova-Ertl, T. et al. Trial of N-Acetyl-l-Leucine in Niemann-Pick disease type C. N. Engl. J. Med. 390, 421\u2013431 (2024).","journal-title":"N. Engl. J. Med."},{"key":"32984_CR24","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1007\/s00415-013-7016-x","volume":"260","author":"M Strupp","year":"2013","unstructured":"Strupp, M. et al. Effects of acetyl-dl-leucine in patients with cerebellar ataxia: a case series. J. Neurol. 260, 2556\u20132561 (2013).","journal-title":"J. Neurol."},{"key":"32984_CR25","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.4103\/1673-5374.335146","volume":"17","author":"C Sarkar","year":"2022","unstructured":"Sarkar, C. & Lipinski, M. M. N-acetyl-L-leucine: a promising treatment option for traumatic brain injury. Neural Regeneration Res. 17, 1957\u20131958 (2022).","journal-title":"Neural Regeneration Res."},{"key":"32984_CR26","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/tra.12726","volume":"21","author":"A Martello","year":"2020","unstructured":"Martello, A., Platt, F. M. & Eden, E. R. Staying in touch with the endocytic network: the importance of contacts for cholesterol transport. Traffic 21, 354\u2013363 (2020).","journal-title":"Traffic"},{"key":"32984_CR27","doi-asserted-by":"publisher","first-page":"13566","DOI":"10.1073\/pnas.251485198","volume":"98","author":"P Gupta","year":"2001","unstructured":"Gupta, P. et al. Disruption of PPT1 or PPT2 causes neuronal ceroid lipofuscinosis in knockout mice. Proc. Natl. Acad. Sci. U.S.A. 98, 13566\u201313571 (2001).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"32984_CR28","doi-asserted-by":"publisher","first-page":"eadj1445","DOI":"10.1126\/scitranslmed.adj1445","volume":"17","author":"E. Zi\u00f3\u0142kowska","year":"2025","unstructured":"Zi\u00f3\u0142kowska, E. et al. Gene therapy ameliorates bowel dysmotility and enteric neuron degeneration and extends survival in lysosomal storage disorder mouse models. Sci. Transl. Med. 17, eadj1445 (2025).","journal-title":"Sci. Transl. Med."},{"key":"32984_CR29","doi-asserted-by":"crossref","unstructured":"Takahashi, K. et al. Gene therapy ameliorates spontaneous seizures associated with cortical neuron loss in a Cln2R207X mouse model. J. Clin. Invest. 133 (2023).","DOI":"10.1172\/JCI165908"},{"key":"32984_CR30","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.nbd.2004.02.010","volume":"16","author":"E Bible","year":"2004","unstructured":"Bible, E., Gupta, P., Hofmann, S. L. & Cooper, J. D. Regional and cellular neuropathology in the palmitoyl protein thioesterase-1 null mutant mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiol. Dis. 16, 346\u2013359 (2004).","journal-title":"Neurobiol. Dis."},{"key":"32984_CR31","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/nan.12658","volume":"47","author":"HR Nelvagal","year":"2021","unstructured":"Nelvagal, H. R., Dearborn, J. T., \u00d8stergaard, J. R., Sands, M. S. & Cooper, J. D. Spinal manifestations of CLN1 disease start during the early postnatal period. Neuropathol. Appl. Neurobiol. 47, 251\u2013267 (2021).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"32984_CR32","doi-asserted-by":"publisher","first-page":"e1072","DOI":"10.1212\/WNL.0000000000201660","volume":"100","author":"K Martakis","year":"2023","unstructured":"Martakis, K. et al. Efficacy and safety of N-Acetyl-l-Leucine in children and adults with GM2 gangliosidoses. Neurology 100, e1072\u2013e1083 (2023).","journal-title":"Neurology"},{"key":"32984_CR33","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13063-020-05009-3","volume":"22","author":"T Fields","year":"2021","unstructured":"Fields, T. et al. A master protocol to investigate a novel therapy acetyl-L-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 gangliosidoses, and ataxia telangiectasia. Trials 22, 84 (2021).","journal-title":"Trials"},{"key":"32984_CR34","doi-asserted-by":"publisher","first-page":"110729","DOI":"10.1016\/j.brainresbull.2023.110729","volume":"202","author":"Z. Xu","year":"2023","unstructured":"Xu, Z. et al. N-acetyl-L-leucine protects MPTP-treated parkinson\u2019s disease mouse models by suppressing Desulfobacterota via the gut-brain axis. Brain Res. Bull. 202, 110729 (2023).","journal-title":"Brain Res. Bull."},{"key":"32984_CR35","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1242\/jcs.146365","volume":"129","author":"G Napolitano","year":"2016","unstructured":"Napolitano, G. & Ballabio, A. TFEB at a glance. J. Cell Sci. 129, 2475\u20132481 (2016).","journal-title":"J. Cell Sci."},{"key":"32984_CR36","doi-asserted-by":"publisher","first-page":"e2213670120","DOI":"10.1073\/pnas.2213670120","volume":"120 7","author":"Y Lin","year":"2023","unstructured":"Lin, Y. et al. A small-molecule drug inhibits autophagy gene expression through the central regulator TFEB. Proc. Natl. Acad. Sci. U.S.A. 120 7, e2213670120 (2023).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"32984_CR37","first-page":"e1072","volume":"100","author":"K Martakis","year":"2022","unstructured":"Martakis, K. et al. Efficacy and safety of N-Acetyl-l-Leucine in children and adults with GM2 gangliosidoses. Neurology 100, e1072\u2013e1083 (2022).","journal-title":"Neurology"},{"key":"32984_CR38","doi-asserted-by":"publisher","first-page":"105855","DOI":"10.1016\/j.nbd.2022.105855","volume":"173","author":"Z Gu","year":"2022","unstructured":"Gu, Z. et al. TFEB in alzheimer\u2019s disease: from molecular mechanisms to therapeutic implications. Neurobiol. Dis. 173, 105855 (2022).","journal-title":"Neurobiol. Dis."},{"key":"32984_CR39","first-page":"10","volume":"16","author":"H Chen","year":"2024","unstructured":"Chen, H. et al. From the regulatory mechanism of TFEB to its therapeutic implications. Cell. Death Discov. 16, 10 (2024).","journal-title":"Cell. Death Discov"},{"issue":"22","key":"32984_CR40","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1093\/hmg\/11.22.2709","volume":"11","author":"S. L. Cotman","year":"2002","unstructured":"Cotman, S. L. et al. Cln3(Deltaex7\/8) knock-in mice with the common JNCL mutation exhibit progressive neurologic disease that begins before birth. Hum. Mol. Genet. 11 (22), 2709\u20132721 (2002).","journal-title":"Hum. Mol. Genet."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32984-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32984-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32984-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:54:04Z","timestamp":1781625244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-32984-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["32984"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-32984-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"23 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JDC has received research support from BioMarin Pharmaceutical Inc., Abeona Therapeutics Inc., REGENXBIO Inc. and Neurogene, and is a consultant for JCR Pharmaceuticals. FMP is an academic cofounder of IntraBio.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal procedures were performed in accordance with National Institutes of Health (NIH) guidelines under protocols 2018\u2009\u2212\u20090215, 21\u20130292, and 24\u20130232 approved by the Institutional Animal Care and Use Committee (IACUC) at Washington University School of Medicine in St. Louis, MO.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"3033"}}